证券日报网讯 1月23日，雅本化学在互动平台回答投资者提问时表示，目前公司医药业务聚焦创新医药 中间体、原料药CDMO服务，暂未涉及创新药自主研发与商业化布局。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its commitment to a global development strategy, with the EU region being a key area for overseas operations [1] Group 1: Business Strategy - The company has established and operates a mature regional center in Germany, enhancing local service capabilities and customer response efficiency [1] - The EU region is a significant source of overseas revenue and supports the sustainable and healthy development of the company's international business [1] Group 2: Sales Model - The company adopts a direct sales model in major global markets, including the EU, allowing it to directly serve local customers [1] - This approach enables the company to deeply understand market demands and provide efficient, professional pre-sales, sales, and post-sales services [1] - The company aims to build strong customer relationships and enhance brand influence through its direct engagement strategy [1]

Core Viewpoint - The company primarily engages in the research, production, and sales of steroid drug raw materials, with a focus on progesterone products for gynecological and family planning medications [2] Group 1: Company Operations - The company is involved in the development, production, and sales of steroid drug raw materials [2] - The company's fundraising projects and steroid raw material production projects include the extension of progesterone products for downstream applications [2] - The company's products are categorized based on sales regions, which include domestic and international sales [2]

Core Viewpoint - Beilu Pharmaceutical announced that its subsidiary, Zhejiang Haichang Pharmaceutical, received a new High-tech Enterprise Certificate, indicating its continued recognition as a high-tech entity in the industry [1]. Group 1: Company Announcement - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has been re-certified as a high-tech enterprise by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1]. - The certificate number is GR202533008197, with an issuance date of December 19, 2025, and it is valid for three years [1]. - This re-certification follows the expiration of the previous high-tech enterprise certificate held by Haichang Pharmaceutical [1].

Group 1 - The company, Jinkai Biotechnology, announced an expected net profit attributable to shareholders for the year 2025 ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [2]

Group 1 - The company LuKang Pharmaceutical held its 12th temporary board meeting on January 23, 2026, to discuss the proposal regarding the use of raised funds to replace previously invested self-raised funds [1] - The meeting was conducted in a hybrid format, combining in-person and communication methods [1] Group 2 - Local state-owned assets have begun purchasing foreclosed properties, acquiring over 60 units in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit, while the average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]

南财智讯1月23日电，鲁抗医药公告，公司于2026年1月23日召开第十一届董事会第十二次（临时）会 议，审议通过了《关于使用部分闲置募集资金进行现金管理的议案》。公司将使用不超过3.10亿元暂时 闲置募集资金进行现金管理，投资期限不超过12个月，在上述额度和期限内，资金可循环滚动使用。资 金来源为暂时闲置募集资金，投资方向包括安全性高、流动性好的保本型产品，如协定存款、定期存 款、大额存单等。该事项不会影响募集资金投资项目进度和公司正常生产经营。 ...

拓新药业1月23日公告，预计2025年归母净利润亏损5400万元–7300万元，上年同期亏损1988.49万元。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 每经AI快讯，联环药业1月23日晚间发布业绩预告，预计公司2025年年度归属于上市公司股东的净利润 区间为-9900万元人民币至-8300万元人民币，与上年同期相比将减少约1.67亿元人民币到约1.83亿元人 民币，业绩由盈转亏。 ...

每经AI快讯，富祥药业1月23日晚间发布公告称，江西富祥药业股份有限公司董事会于近日收到公司副 总经理陈应惠先生提交的书面辞职报告，陈应惠先生因个人原因申请辞去公司副总经理职务，辞职后不 再担任公司任何职务。 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 （记者 王晓波） ...